1. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study 
Clare Atherton, John Jones, Brian McKaig, James Bebb, Rob Cunliffe, Jake Burdsall, Joanne Brough, Diane Stevenson, Johanne Bonner, Christiane Rordorf, Graham Scott, Janice Branson, Christopher J Hawkey 
Clinical Gastroenterology and Hepatology 
Volume 2, Issue 2, Pages (February 2004)
DOI: /S (03)

2. Figure 1
Disposition of subjects. ∗This subject is included in all listings and statistical analyses under the treatment sequence he or she actually received and not the one to which the subject was randomized.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (03) )

3. Figure 2
Whole blood COX-2 and COX-1 activity before and after each treatment. Paired data for individual subjects are shown.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (03) )

4. Figure 3
Relationship between drug levels and ex vivo whole blood COX-2 (measured as LPS-stimulated PGE2, left) and COX-1 (measured as serum TXB2, right) activity.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (03) )

5. Figure 4
Effect of lumiracoxib and naproxen on gastric PGE2 levels. Results are adjusted means (95% CI). P < 0.001, P < 0.01 vs. placebo.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (03) )

6. Figure 5
Number of gastroduodenal erosions in each subject. Individual lines represent the number of erosions seen in each subject at the end of each treatment period (random treatment order). No erosions were seen in any subject during treatment with lumiracoxib, whereas erosions were seen in 75% of subjects during treatment with naproxen.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (03) )

7. Figure 6
Frequency distribution of Lanza scores on day 9 by treatment group for gastric sites.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (03) )

8. Figure 7
Effect of lumiracoxib and naproxen on small (0–5-hour) and large bowel (5–24-hour) permeability. Results are adjusted means (95% CI). P < vs. placebo and lumiracoxib.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (03) )